Primary Care Clinics in Emily, MN Accepting Medicare
1 Primary Care Clinics found. Showing 1 - 1
 Essentia Health St. Joseph's Emily Clinic Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 20918 County Road 1, Emily, MN 56447 Phone: 218-763-4800 Fax: 218-763-4805 |
News Archive
Custom or Wavefront-guided LASIK produces superior vision quality compared to traditional LASIK eye surgery
An independent researcher reporting at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) finds that "Custom" or Wavefront-guided LASIK produces superior vision quality compared to traditional LASIK eye surgery. "While conventional LASIK is good, we're finding that wavefront guided LASIK yields sharper and higher quality vision, and higher patient satisfaction compared to conventional LASIK.
Dilon Technologies delivers enhanced imaging capabilities
Dilon Technologies, Inc., the leader in molecular breast imaging, today announced the release of the newest Dilon 6800 Software update including enhancements for both breast and general nuclear medicine applications image processing. The new software functionalities complement the Slant15 Collimator for breast imaging and the Low Energy High-Resolution (LEHR) Collimator for general nuclear medicine applications, both released earlier this year as purchase options for the Dilon 6800 gamma camera.
High quality diet during mid-to-late adulthood may prevent adverse metabolic consequences
A new study in Obesity investigated the impact of diet quality in mid-to-late-adulthood on visceral and liver fat not solely relying on Body Mass Index.
Aton Pharma acquires Timoptic product line from Merck & Co
Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the Timoptic product line from Merck & Co., Inc. Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee
The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR®
› Verified 7 days ago